Safety and Efficacy Study of NVC-422 on Bacteriuria in Catheterized Patients

Asymptomatic Bacteriuria Clinical Trial

Official title:

A Phase IIa Open Label Study to Evaluate the Safety and Antimicrobial Effects of NVC-422 on Bacteriuria in Chronically Catheterized Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00781339
• Other study ID #: CL0803
• Secondary ID: H-23765
• Status: Completed
• Phase: Phase 2
• First received: October 28, 2008
• Last updated: September 6, 2011
• Start date: October 2008
• Est. completion date: March 2010

Study information

• Verified date: September 2011
• Source: NovaBay Pharmaceuticals, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this clinical trial is to study the effects of NVC-422 instilled into the bladder in reducing bacteria in the urine.

Description:

Catheter-associated urinary tract infection (CAUTI) is a major healthcare problem in the U.S., accounting for approximately 40% of all hospital acquired infections. Microorganisms can colonize the catheter extraluminally or intraluminally, and are often protected in a biofilm environment. Nearly all patients catherized for 30 days or longer will develop bacteriuria, or the presence of bacteria in normally sterile urine. Ten to twenty percent of these patients will develop a symptomatic CAUTI. In a further 1-4%, the infection will spread into the kidneys or bloodstream, leading to potentially lethal bacteremia.

Currently, there is no bladder irrigation solution that can reduce or eliminate CAUTI. A bladder instillation solution that can keep the bladder and catheter substantially free of bacteria and biofilm is expected to provide a practical and cost-effective means of minimizing CAUTIs.

NVC-422 is a topical, non-antibiotic, fast acting, broad spectrum anti-microbial, which exhibits potential for the rapid decolonization of a range of urologic pathogens, including Escherichia Coli (E. coli), Enterococcus spp., P. mirabilis and others. In vitro studies with NVC-422 have also shown that it is capable of penetrating a biofilm and effectively killing the contained microbes.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: March 2010
• Est. primary completion date: March 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients or their guardians are willing and able to provide informed consent

• Age > 18 years

• Condition requiring chronic transurethral catheterization for at least 1 month prior to enrollment

• Indwelling transurethral catheter not scheduled for exchange for at least 1 week from first treatment

• Documented asymptomatic bacteriuria as defined in the protocol

• Vital signs within the following limits: blood pressure 90 to 160 mm Hg systolic and 50 to100 mm Hg diastolic, pulse rate 45 to 100 bpm, respiratory rate 8 to 24 respirations per minute, oral body temperature 35.5ºC to 38.0ºC

• Screening must occur within 14 days of enrollment into the study

Exclusion Criteria:

• Unwillingness/inability to fulfill the requirements of the study

• History of hepatitis B or C, HIV, AIDS, or other immunodeficiency disease

• Systemic antibiotics within 7 days of enrollment

• Any condition that, in the opinion of the principal investigator, would make the subject unsuitable for the study or place the subject at additional risk.

• Any investigational drug or investigational device within 30 days of enrollment in the study

• Women who are pregnant or lactating; or of child-bearing potential unless using highly effective birth control method for 1 month prior to and during the study

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Asymptomatic Bacteriuria
• Bacteriuria

Intervention

Drug:
• sodium 2-(dichloroamino)-2-methylpropane-1-sulfonate monohydrate
0.1% NVC-422 in saline, up to 100 mL, Study Part 1 - once on Day 1 held in the bladder for 1 hour; Study Part 2 (Part 2a - 0.1% NVC-422, Part 2b - 0.2% NVC-422), once daily for 7 days, held in the bladder for 1 hour

Locations

Country	Name	City	State
United States	Michael E. Debakey V.A. Medical Center	Houston	Texas

Sponsors (1)

Lead Sponsor	Collaborator
NovaBay Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluate the safety and antimicrobial effect (and its duration) of NVC-422 in urine following bladder instillation in chronically catheterized subjects with bacteriuria		7-10 days	Yes
Secondary	Assess urine concentration of NVC-422 and its primary metabolite (2,2-DMT) following bladder instillation		1-7 days	No
Secondary	Assess plasma concentration of NVC-422 and its primary metabolite (2,2-DMT) following bladder instillation		1-7 days	No